peterschreiber.media – stock.adobe.com
Berlin German Society of Gastroenterology, Digestion and SubstanceDiseases (DGVS) sees, despite a recent in the review Nature Communications published work no link between the intake of gastric acid blockers and the development of allergies. According to the experts of the DGVS, the study is not designed to answer the question of whether Surehemmer is favorable to the emergence of allergies.
Individual studies with a very limited scientific scope should not automatically challenge the evidence from many scientific studies, which are now the basis of medical practice. Otherwise, you can quickly reach a gray area where it can be difficult to ensure reliable patient care, said Christian Trautwein, director of the RWTH Aachen Medical Clinic III and spokesperson for the DGVS for the media.
The study criticized revealed that in Austria, patients who had been prescribed as gastric acid inhibitors or as mucosal protection agents had received twice as many treatments as other patients under POS to treat their allergies. The population study aims to confirm the hypothesis that inhibition of gastric function increases the ability to allergy.
Patients from the Vienna Health Authority in Austria, who had been prescribed gastric acid inhibitors or mucosal protective agents, then received twice as many prescriptions as other patients on POS for allergy treatment. The population study published in Nature Communications (2019; 10: 3298) aims to propose a hypothesis
Herbert Koop, expert in DGVS, doctor of internal medicine and gastroenterology and former head doctor of the department of general internal medicine and gastroenterology of the HELIOS-Klinikum Berlin-Buch, summarizes the criticisms addressed to the professional society in the study:
On the one hand, different drugs have been studied: sucralfates, which have virtually no influence on gastric pH, H2 blockers, classified as moderately active over-inhibitors, and proton pump inhibitors (PPIs). as powerful inhibitors. According to the study, all substances increase the risk of developing an allergy. Thus, there is no correlation with the degree of suppression. Therefore, one may wonder if the Surehemmung in connection with the Allergieentstehung should be seen, so, Koop.
On the other hand, the analysis regarding the emergence of allergies would be based only on the prescription of drugs supposed to indicate the presence of an allergy. The data on allergy diagnoses themselves were not available. That too is a weak point, according to the expert. Basically, the fact that a drug has been prescribed, is not suitable to derive the cause of other new diseases such as allergies here.
No additional information on patients
Also in the study was not sufficiently distinguished, what allergies it was. In addition, according to Koop, another essential aspect is missing: the authors would not have taken into account any additional information on patients. It is scientifically proven that patients on PPI, for example, differ considerably from other patients: they are generally older, have more comorbidities, take more drugs. This influence could not be assessed in the current published study because investigators obviously did not have access to such important data about the drug, or even better to the diagnostic data, he criticized. Because of its design and data situation, the study does not say whether over-inhibition promotes the development of allergies, is the conclusion of the expert society. © HIL / Good king News